In the article by Moon et al, which appeared in the February 2012 issue of the journal (Arterioscler Thromb Vasc Biol. 2012;32:236–246. DOI: 10.1161/ATVBAHA.111.241356), an incorrect figure appeared for Figure 5. The correct figure and its legend appear below. The online version has been corrected.

**Figure 5.** Treatment of floxed mice with Sreb-1c ASO before acute depletion of hepatic Pten blocks the increase in hepatic triglycerides (TG) but does not result in decreased apolipoprotein B (apoB) secretion. Floxed mice were pretreated for 4 weeks with Sreb-1c ASO before being injected with recombinant adenovirus containing either Cre (Cre) or Gfp (Gfp). Studies were performed 4 days after injection of virus. **A**, Insulin signaling was increased significantly in mice receiving Cre adenovirus as assessed by the phospho-v-akt murine thymoma viral oncogene homolog (AKT), (p-AKT)/AKT ratio. **B**, Sreb-1c and Fas gene expression were not increased in ASO-pretreated mice receiving Cre adenovirus. **C**, Hepatic TG levels were not significantly increased and were in the normal range in ASO-pretreated mice receiving Cre adenovirus. **D**, TG secretion was not significantly increased in ASO-pretreated mice receiving Cre adenovirus. **E** and **F**, Secretion rates of apoB100 and apoB48 were not affected in ASO-pretreated mice receiving Cre adenovirus. n=3 for each group. *P<0.01.
Correction

*Arterioscler Thromb Vasc Biol.* 2012;32:e23
doi: 10.1161/ATV.0b013e31824d8afa

*Arteriosclerosis, Thrombosis, and Vascular Biology* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/32/3/e23